Lead Product(s) : ELX-02
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ELX-02 (exaluren sulfate) is a small molecule drug candidate designed to restore production of full-length functional proteins. It is being developed for the treatment of alport syndrome.
Brand Name : ELX-02
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 09, 2023
Lead Product(s) : ELX-02
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : ELX-02
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. It is being developed for the treatment of CF patients with nonsense mutations.
Brand Name : ELX-02
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 24, 2023
Lead Product(s) : ELX-02
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : ELX-02
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. It is being developed for the treatment of CF patients with nonsense mutations.
Brand Name : ELX-02
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 27, 2023
Lead Product(s) : ELX-02
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : ELX-02
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins (collagen IV and collagen VII). It has been granted fast track designation for the treatment of CF patients with nonsense mutations.
Brand Name : ELX-02
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 25, 2023
Lead Product(s) : ELX-02
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : ELX-02
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins,for the treatment of CF patients with nonsense mutations.
Brand Name : ELX-02
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 01, 2022
Lead Product(s) : ELX-02
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : ELX-02,Ivacaftor
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Evidence of activity for ELX-02 was observed, as patients with higher baseline sweat chloride levels demonstrated increased responses as indicated by SCC (p=0.00013 at Day 35).
Brand Name : ELX-02
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 14, 2022
Lead Product(s) : ELX-02,Ivacaftor
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : ELX-02
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : In recently published preclinical studies, ELX-02 is a small molecule drug candidate designed to restore production of full-length functional proteins has demonstrated readthrough in COL4A5 mutations, which represent 85% of nonsense mutations in this pop...
Brand Name : ELX-02
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 30, 2022
Lead Product(s) : ELX-02
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : ELX-02
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : The Cystic Fibrosis Foundation
Deal Size : $19.5 million
Deal Type : Funding
CF Foundation Funds Expansion of Clinical Trial Program for Potential Nonsense Mutations Therapy
Details : The new funding will enable the company to expand the studies to determine whether the combination of ELX-02 with a cystic fibrosis transmembrane conductance regulator (CFTR) modulator results in increased biological activity over ELX-02 alone.
Brand Name : ELX-02
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 29, 2022
Lead Product(s) : ELX-02
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : The Cystic Fibrosis Foundation
Deal Size : $19.5 million
Deal Type : Funding
Lead Product(s) : ELX-02,Ivacaftor
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : In preclinical studies, Class 1 CF patient organoids had a 2- to 3-fold higher swelling response with a combination of ELX-02 and Kalydeco than with ELX-02 as a monotherapy. Topline results are expected by the end of the first half of 2022.
Brand Name : ELX-02
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 17, 2021
Lead Product(s) : ELX-02,Ivacaftor
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : ELX-02
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Hercules Capital
Deal Size : Undisclosed
Deal Type : Financing
Eloxx Pharmaceuticals Secures Debt Facility of Up to $30 Million from Hercules Capital
Details : This non-dilutive financing will provide additional capital to advance the product pipeline, including ELX-02, which is currently in Phase 2 clinical trials in cystic fibrosis patients affected by nonsense mutations, as well as preclinical programs.
Brand Name : ELX-02
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 05, 2021
Lead Product(s) : ELX-02
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Hercules Capital
Deal Size : Undisclosed
Deal Type : Financing
LOOKING FOR A SUPPLIER?